Keywords: HPV; human papilloma virus; CC; cervical cancer; EC; endometrial cancer; CIN; cervical intraepithelial neoplasia; VIN; vulvar intraepithelial neoplasia; VaIN; vaginal intraepithelial neoplasia; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1; pr
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: AE; adverse event; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; EGFR; epidermal growth factor receptor; FAK; focal adhesion kinase; IGFR; insulin growth factor receptor; MPM; malignant pleural mesothelioma; MTD; maximum tolerated dose; mTOR; mamma
Keywords: Immune-related adverse events; Immune checkpoint blockade; Cytotoxic T-lymphocyte-associated antigen 4; Anti-PD-1 antibody; Tumour neoantigen;
Keywords: Ago2; argonaute 2; CDE; clathrin-dependent endocytosis; CIE; clathrin-independent endocytosis; CPP; cell penetrating peptides; CTLA4; cytotoxic T-lymphocyte-associated antigen 4; ECM; extracellular matrix; EPR; enhanced permeability and retention; ERC; en
Keywords: BRAF; v-raf murine sarcoma viral oncogene homolog; MEK; MAP kinase-ERK kinase; KIT; V-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1/PD-L1; programmed death-1/ programmed death-1 li
Keywords: Radiation; Immunotherapy; Dose; Fractionation; MHC-I; major histocompatibility class I; ICAM-1; intercellular adhesion molecules-1; CEA; carcinoembryonic antigen; CTL; cytotoxic T cells; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; gp 100; glycopr
Keywords: 5-ALA; 5-aminolevulinic acid; 5-FU; 5-fluorouracil; APC; antigen presenting cell; BCC; basal cell carcinoma; CAP; cold atmospheric plasma; CM; cutaneous malignant melanoma; CNP; cerium oxide nanoparticle; CNT; carbon nanotube; COX-2; cyclooxygenase II; CP
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Keywords: PD-L1; Programmed cell death-ligand 1; PD-1; programmed cell death-1; CBIS; cell-based immunization and screening; SCC; squamous cell carcinoma; ACC; adenoid cystic carcinoma; MEC; mucoepidermoid carcinoma; CTLA-4; cytotoxic T-lymphocyte-associated antige
Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency
Keywords: CRC; colorectal cancer; mCRC; metastatic CRC; CTLA4; cytotoxic T-lymphocyte-associated antigen 4; EGFR; epithelial growth factor receptor; HR; hazard ratio; MAP; mitogen-activated protein; mAb; monoclonal antibody; MEK; mitogen-activated protein/extracell
Association of cytotoxic T-lymphocyte-associated antigen 4 genetic polymorphisms with type 1 diabetes in children: A systematic review and meta-analysis
Keywords: Cytotoxic T-lymphocyte-associated antigen 4; Pediatric; Type 1 diabetes; Meta-analysis; Systematic review;
Antitumor dendritic cell-based vaccines: lessons from 20Â years of clinical trials and future perspectives
Keywords: APCs; antigen-presenting cells; cDCs; classical DCs; CTLs; cytotoxic T cells; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; DC; dendritic cell; Dex; dendritic cell-derived exosomes; EMA; European Medicines Agency; FDA; Food and Drug Administratio
Research ArticleA clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Keywords: HCV; hepatitis C virus; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; RECIST; Response Evaluation Criteria in Solid Tumor; TTP; time to progression; Liver cancer; Immunotherapy; CTLA-4; Treg;